干细胞移植在肝癌治疗中的禁忌与应用

Brief discussion on the taboo and application of stem cell transplantation in the treatment of liver cancer

肝癌是中国病死率第二高的癌症,其隐匿性强,至今缺乏有效治疗手段。近年来广泛开展的干细胞项目,尤其是间充质干细胞(MSCs)移植,虽已被应用于多种疾病的治疗,然而恶性肿瘤是这一移植疗法的禁区已是业内共识。这与干细胞自身的两大特点"自我更新"和"多分化潜能"密切相关。下面就干细胞特别是MSCs成为肿瘤治疗禁忌的原因,以及潜在的应用方式做一概述,以期为这一疗法的进一步研究提供一些参考。

Liver cancer is the second-highest mortality cancer in China.It is highly occult,and there is no effective treatment so far.In recent years,stem cell transplantation,especially mesenchymal stem cell(MSCs)transplantation,has been widely used in the treatment of various diseases.Nevertheless,the industry has reached a consensus that malignant tumors are the forbidden area of this transplantation therapy.This is closely related to the two main characteristics of stem cells themselves,namely"self-renewal"and"pluripotency".The following is an overview of the reasons why stem cells,especially MSCs,have become taboo in tumor treatment and their potential application methods,so as to provide some references for further research on this therapy.